The collaboration will explore the potential of APR-1051 as a therapy for head and neck cancers bearing markers of replication stress.

NEW YORK – Bristol Myers Squibb and 2seventy Bio on Monday entered into a merger agreement in which BMS will acquire 2seventy for $286 million, ending the firms' cost-sharing agreement for the ...

ElevateBio has entered into a multi-year collaboration with Amazon's cloud arm to identify treatment targets and new CRISPR systems.

The collaboration will explore the potential of APR-1051 as a therapy for head and neck cancers bearing markers of replication stress.

NEW YORK – Alterome Therapeutics said on Monday it has started treating patients with KRAS-mutant advanced solid tumors with its KRAS inhibitor ALTA3263 in a Phase I trial.

The firm will use the proceeds to advance its platform technology, R&D, and pre-commercialization activities for its base-editing drugs.

The firm completed enrollment of the first dose expansion cohort evaluating givastomig with immunotherapy and chemotherapy.

Cure51 and Assistance Publique – Hôpitaux de Paris have partnered to identify biomarkers for long-term survival in pancreatic cancer.

NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.

The agency approved it based on two Phase III studies showing the drug to be as effective as another combination therapy at improving lung function.